8-K 1 form8-k.htm






Washington, D.C. 20549





Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 29, 2021



(Exact name of registrant as specified in its charter)


Delaware   001-35570   20-2932652

(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer

Identification No.)


100 Overlook Center, Suite 102

Princeton, New Jersey 08540


(Address of principal executive offices)

Registrant’s telephone number, including area code: (609) 375-2227



(Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 Par Value   SONN   The Nasdaq Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company [  ]


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]







Item 7.01. Regulation FD Disclosure.


On March 29, 2021, Sonnet BioTherapeutics Holdings, Inc. (the “Company”) issued a press release regarding the Company’s business update on its ongoing programs. The press release is attached hereto as Exhibit 99.1 and incorporated by reference in this Item 7.01.


The information presented in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.


Item 8.01. Other Events.


On March 29, 2021, the Company announced a business update on its ongoing programs, as summarized below:


  SON -1010 (FHAB-IL12): The Company has completed nonhuman primate (“NHP”) GLP toxicity studies with SON-1010 and is awaiting data to prepare an IND submission, while working in parallel to initiate clinical trials during the second half of this year. Prior to IND submission, the Company will initiate pre-IND interactions with the U.S. Food and Drug Administration, which are expected during the second quarter, and will work to finalize the first-in-human protocol, along with selecting a contract research organization (“CRO”) to perform the studies. CMC activities are on schedule to deliver GMP material prior to the IND filing.
  SON-080 (Fully Human IL-6) – Chemotherapy Induced Peripheral Neuropath (“CIPN”):  With successful GLP toxicity studies completed, the CMC manufacturing is well underway, and product is expected to be available for a clinical trial commencing during the second half of this year.  Plans have been initiated to complete the study design protocol for a Phase 1b/2a study, as well as the completion of diligence and selection of a CRO.
  SON-081 (Fully Human IL-6) – Diabetic Peripheral Neuropathy (“DPN”): The Company anticipates completing the partnership deal in South East Asia during April 2021 that the Company expects will position New Life Therapeutics (“NLT”) to fund and progress the asset forward into a Phase 1b/2a clinical trial.  NLT has elected to focus on the acceleration of the development of low dose IL-6 for DPN at this time, and to hold an option to the CIPN indication for several months following the execution of a definitive agreement.  The Company anticipates that clinical trial initiation will occur during the second half of this year. The Company has recently obtained positive initial comparability data from the new batch being manufactured using an updated process and awaits final study completion and reports of product comparability, prior to IND filing.
  SON-1210 (IL12-FHAB-IL15): The Company’s first bispecific candidate is undergoing cell line and process development.  The Company has engaged a novel intensified perfusion manufacturing process to generate clinical grade material and expects completion of NHP studies in the second half of this year with an IND submission during the first half of 2022.
  SON-2014 (GMcSF-FHAB-IL18): In addition to GMcSF-FHAB-IL18, the Company has manufactured bi-specific preclinical constructs of IL18-FHAB-IL12 and IL12-FHAB-GMcSF that are being evaluated for in vivo efficacy, biomarker profiles and fluorescence-activated cell sorting (“FACS”) assessment in single dose and multi-dose preclinical studies.


Upon completion of the preclinical efficacy evaluation in the second quarter of this year, the Company intends to initiate commercial cell line development necessary for future clinical trials. An IND submission for SON-2014 is currently targeted for the second half of 2022.


  SON-3015 (Anti-IL6-FHAB-Anti-TGFβ): The Company is in the discovery phase of SON-3015 development and is currently panning the candidate for binding and stability, after which the preclinical bispecific product will be evaluated in a mice model, expected during the second half of 2021. The Company is planning to initiate commercial cell line development in the first quarter of 2022.
  INTELLECTUAL PROPERTY: The Company has received Notice of Allowance from the United States Patent and Trademark Office for its first issued patent on the FHAB delivery technology.  Formal issuance is expected during the balance of the first half of 2021.


Item 9.01. Financial Statements and Exhibits.


(d) Exhibits.


Exhibit No.   Exhibit
99.1   Press Release, dated March 29, 2021







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


  Sonnet BioTherapeutics Holdings, Inc.
  a Delaware corporation
Date: March 30, 2021 By: /s/ Pankaj Mohan, Ph.D.
  Name:  Pankaj Mohan, Ph.D.
  Title: Chief Executive Officer